Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix
Seeking Alpha
Friday, April 25, 2014 - 11:21am
tags:
antibiotics, Cubist Pharma, Durata Therapeutics, Cellceutix
FDA will meet to review behavior changes and psychiatric risks of Pfizer's stop-smoking drug
Yahoo/AP
Friday, April 25, 2014 - 11:20am
tags:
FDA, Pfizer, Chantix, smoking cessation
Chinese Pharma Looks Healthy as Price Controls Ease, Consumers Spend More
TheStreet.com
Friday, April 25, 2014 - 11:19am
tags:
China
EU agency backs GSK melanoma drug, wider use of Bayer's Nexavar
Yahoo/Reuters
Friday, April 25, 2014 - 11:02am
tags:
GSK, melanoma, Europe, Bayer, Nexavar, Mekinist, thyroid cancer
Allergan made a pass at Shire before Valeant came calling
Fierce Biotech
Friday, April 25, 2014 - 9:53am
tags:
Valeant Pharmaceuticals, M&A, Allergan, Shire
Allergan can do better than Valeant offer, investor says
Mass Device
Friday, April 25, 2014 - 9:18am
tags:
Valeant Pharmaceuticals, Allergan, M&A
C.R. Bard blows away sales and earnings expectations in Q1
Mass Device
Friday, April 25, 2014 - 9:17am
tags:
CR Bard, earnings, devices
BMS extends deal with Samsung as its pipeline percolates with more biologics
Fierce Pharma
Friday, April 25, 2014 - 9:08am
tags:
Bristol-Myers Squibb, Samsung BioLogics
Sarepta's Still a Gamble, Even With FDA Reversal
Motley Fool
Friday, April 25, 2014 - 8:31am
tags:
FDA, Sarepta Therapeutics, Duchenne Muscular Dystrophy, eteplirsen
Emergent's BioThrax Gets Orphan Drug Status
Yahoo/Zacks.com
Friday, April 25, 2014 - 8:27am
tags:
Emergent BioSolutions, BioThrax, orphan drugs, anthrax, vaccines
Cytokinetics says Lou Gehrig's drug fails mid-stage trial
Yahoo/Reuters
Friday, April 25, 2014 - 8:22am
tags:
Lou Gehrig's disease, Cytokinetics, ALS, Tirasemtiv
AbbVie shares rise after earnings top forecasts
Marketwatch
Friday, April 25, 2014 - 8:18am
tags:
AbbVie, earnings
Best Weapon In The War On Cancer? Data Sharing
Forbes
Friday, April 25, 2014 - 8:18am
tags:
data sharing, clinical trials, cancer, oncology, Project Data Sphere
Novartis INSTEAD study for Onbrez Breezhaler meets primary objective
Yahoo/Fly on the Wall
Friday, April 25, 2014 - 8:14am
tags:
Novartis, Onbrez Breezhaler, COPD
Prestige Brands to buy Insight Pharma for $750 million
Marketwatch
Friday, April 25, 2014 - 8:13am
tags:
Prestige Brands, M&A, Insight Pharma
Alexion Posts Strong Earnings in Q1
Yahoo/Zacks.com
Thursday, April 24, 2014 - 5:58pm
tags:
Alexion, earnings
FDA approves Roche HPV DNA test for primary cervical cancer screening
Yahoo/Fly on the Wall
Thursday, April 24, 2014 - 5:56pm
tags:
FDA, Roche, DNA, cervical cancer, HPV, cobas HPV test
UCB Sales Rise in Q1
Yahoo/Zacks.com
Thursday, April 24, 2014 - 5:55pm
tags:
UCB Pharmaceuticals, earnings
Celgene enters deal potentially worth over $2.5 billion for Nogra Pharma's Crohn's disease drug
First Word Pharma
Thursday, April 24, 2014 - 11:36am
tags:
Celgene, Nogra Pharma, Crohn's Disease, GED-0301
Allergan sales force key to Valeant chief's plans for post-merger growth
Fierce Pharma Marketing
Thursday, April 24, 2014 - 11:32am
tags:
Allergan, Valeant Pharmaceuticals, drug reps, M&A

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.